Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Hepatology. 2015 Aug 22;62(4):1047–1058. doi: 10.1002/hep.27971

Table 5.

Correlates of SVR in patients infected with Genotype 3 HCV

Relapse SVR P-value OR (95% CI)a
Unadjusted Adjusted
Treatment Duration (wks) 12 36 (46.2%) 26 (33.3%) 0.01b 1 [Reference]
6.0 (1.73, 28.1)
1 [Reference]
1.80 (1.59, 31.0)*
16 3 (3.8%) 13 (16.7%)

Clinical Trial FUSION 9 (11.5%) 18 (23.1%) 0.06b 1 [Reference]
0.35 (0.13, 0.91)
--
POSITRON 30 (38.5%) 21 (26.9%)

Log10HCV RNA baselinee 6.064 (0.804) 6.334 (0.750) 0.13c 1.58 (0.885, 2.966) --

Log10IP-10 baselined 2.331 (0.262) 2.459 (0.298) 0.05c 1.19 (1.01, 1.43) --

Log10MIP1β week 1d 1.124 (0.166) 1.215 (0.234) 0.05c 1.26 (1.00, 1.61) 1.40 (1.08, 1.89)*

Log10IP-10 week 2d 1.953 (0.173) 2.062 (0.345) 0.09c 1.17 (0.99, 1.43) --

Log10MIP1β week 2d 1.111 (0.132) 1.202 (0.258) 0.06c 1.25 (1.00, 1.61) --

A Log10IP-10 w0-1d 0.328 (0.227) 0.402 (0.235) 0.16c 1.15 (0.95, 1.42) 1.34 (1.06, 1.75)*

Variables meeting p-value <0.2 threshold for inclusion in initial multivariable analysis are reported. Percentages have been rounded and might not total 100.

a

Univariable (unadjusted) and multivariable (adjusted) ORs are presented.

b

P-values calculated by Fisher Exact Test

c

P-values calculated by independent sample t tests

d

Odds ratios were calculated per 0.1 unit increase

e

Odds ratio was calculated per 1 log10 increase in viral load

“--” indicates variables that were dropped from the exploratory multivariable model

Mean and (SD) noted under Relapse and SVR for all continuous variables